Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 29,614 shares at $8.23 ($244K) on 2023-11-20, disclosed to the SEC on 2023-11-21.
Open-market sale of $244k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.23 | 14,807 | $122K | 50.0% |
| 2 | $8.23 | 14,807 | $122K | 50.0% |
| Total | $8.23 avg | 29,614 | $244K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-08-21 | $319K | — | Filing → |